These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23235917)

  • 21. [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
    Pikó B; Bassam A; Nagy KA; Török E; Vághy R; Vargáné Tamás R; Puskásné Szatmári K
    Magy Onkol; 2012 Sep; 56(3):166-70. PubMed ID: 23008824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M; Simeonovic M; Grommes C
    Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
    Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
    Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
    Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
    J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
    Omar AI
    J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.
    Motoo N; Hayashi Y; Shimizu A; Ura M; Nishikawa R
    Jpn J Clin Oncol; 2019 Dec; 49(11):1016-1023. PubMed ID: 31665343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
    Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
    Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
    Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
    Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma.
    D'Alessandris QG; Martini M; Cenci T; Capo G; Ricci-Vitiani L; Larocca LM; Pallini R
    Neurology; 2015 May; 84(18):1906-8. PubMed ID: 25862796
    [No Abstract]   [Full Text] [Related]  

  • 34. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.
    Keenan BP; Abuav R
    Arch Dermatol; 2010 May; 146(5):577. PubMed ID: 20479324
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab: overview of the literature.
    Braghiroli MI; Sabbaga J; Hoff PM
    Expert Rev Anticancer Ther; 2012 May; 12(5):567-80. PubMed ID: 22594892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
    [No Abstract]   [Full Text] [Related]  

  • 39. [MR imaging for accurate response monitoring in glioblastoma multiforme during bevacizumab therapy].
    Korn A; Braun C; Fenchel M; Ernemann U; Horger M
    Rofo; 2012 May; 184(5):397-401. PubMed ID: 22576602
    [No Abstract]   [Full Text] [Related]  

  • 40. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
    Wilkes GM
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.